Introduction
While cancer cells use a number of strategies to avoid immune-mediated detection and killing during tumorigenesis, leveraging the immune system has become a viable strategy for treating human cancers within the past five years [1, 2] . Optimal anti-tumor immune responses are specific to cancer cells, adaptable to changes in cancer cell gene expression, and provide durable disease control; these features are not readily achieved by conventional oncology strategies that aim to kill tumor cells directly. The recent FDA approval of a dendritic cell (DC)-based vaccine (Provenge) and checkpoint inhibitor antibodies against CTLA-4 and PD-1 have brought immunotherapy to the mainstream of clinical oncology.
Most immuno-oncology strategies aim to generate or unleash the potential of large numbers of functional, high avidity, cytotoxic T lymphocytes (CTL) to briskly infiltrate tumors and kill cancer cells. Cancer cells are recognized by CTL due to their possible expression of oncogenic virus proteins, unique mutated proteins, or abnormal expression of normal proteins. CTL recognize peptides derived from these proteins presented on major histocompatibility complex class I (MHC I) on the cancer cell surface and destroy the corresponding cell. A number of strategies aiming to induce CTLmediated destruction of cancer cells have been tested clinically. Checkpoint inhibitor antibodies against the T cell inhibitory surface receptors CTLA-4 and PD-1 have shown remarkably durable responses in a number of cancers, but a large fraction of patients fail to respond to these agents, possibly due to a paucity of pre-existing anti-tumor T cells [3, 4] . The number of anti-tumor CTL in a patient can be increased by adoptive cell therapy (ACT) with autologous ex vivo-expanded cancer-reactive T cells or chimeric-antigen receptor (CAR) T cells engineered against known tumor cell surface antigens [5, 6] . These strategies produce durable clinical responses in some cancers, but associated toxicity, the substantial cost of ex vivo cell manipulation, and difficulties in maintaining cell survival and function after transfer into the patient pose challenges for their use. DC-based or synthetic therapeutic cancer vaccines containing irradiated whole tumor cells, tumor lysates, proteins, or peptides, often in combination with immunological adjuvants, have also been tested clinically, but with little durable survival benefit to date [7] .
As only a minority of all cancer patients respond to current immunotherapies, decades of research in the area of cell and drug delivery using biomaterials is now being adapted in efforts to develop more broadly efficacious immuno-oncology strategies. Biomaterials systems offer the ability to protect bioactive molecules or cells, control their spatiotemporal delivery profiles, and allow multiple agents to be delivered from a single platform [8, 9] . These favorable properties potentially allow for reduced toxicity, dose sparing, and improved efficacy compared to conventional bolus delivered therapeutics. This brief review will highlight recently published in vivo biomaterials-based strategies for improving DC and T cell function at various tissue sites for cancer immunotherapy (Figure 1 ). For a more detailed overview of the field of immunoengineering for cancer therapy, the reader is directed to several comprehensive recent reviews [10] [11] [12] [13] [14] .
Programming immune cell function in peripheral tissues
Non-lymphoid peripheral tissues are an initial site of tumor antigen acquisition by DCs, the most potent antigen-presenting cell (APC) [15] . If antigen exposure is accompanied by pro-inflammatory signals released by dying tumor cells, DCs will undergo phenotypic maturation, and migrate to lymph nodes (LN) where they present tumor antigens that stimulate naïve T cells to proliferate and mobilize to tumor sites. Thus, methods to optimally generate antigen-loaded mature DCs and support T cell trafficking and survival in peripheral tissues are of interest in immuno-oncology.
Biomaterials scaffolds delivering immunomodulatory factors can be used as controlled microenvironments to program DC function in situ, obviating the need for ex vivo cell manipulation in conventional DC-based vaccination protocols (Figure 2) . A macroporous PLGA scaffold implanted subcutaneously in mice and releasing granulocyte macrophage colony-stimulating factor (GM-CSF), a cytokine that has been widely explored in oncology, was shown to enrich millions of DCs of multiple subsets within the scaffold [16, 17] . Recruited DCs were simultaneously presented with tumor lysate as an antigen source, and CpG oligonucleotides as a danger signal, leading to their antigen-loading and maturation, respectively. In situ programmed DCs initiated CTL responses that provided therapeutic efficacy against the poorly immunogenic B16-F10 murine melanoma (50% survival with two doses of scaffold vaccine versus 0% with irradiated tumor cells engineered to secrete GM-CSF). Subsequent work showed that a variety of DC recruitment factors and danger signals could be incorporated in these scaffolds with similar anti-tumor efficacy [18, 19] . These promising results have led to an ongoing first-in-human biomaterials vaccine clinical trial (NCT01753089) that has shown acceptable patient safety and the feasibility of manufacturing and delivering patient-specific biomaterial devices in a hospital setting. To avoid the need for surgical implant of a scaffold, an injectable vaccine formed by in situ assembly of high surface area mesoporous silica rods was created [20 ] . By acting as a release depot for GM-CSF, CpG, and tumor antigen, this approach improved CTL and dual Th1/Th2 antibody responses against the model antigen ovalbumin in comparison to the widely used alum adjuvant, leading to protective immunity against ovalbumin-expressing tumor cells. Recently, injectable, spongelike cryogels were fabricated that allow for delivery via a needle [21, 22] , and used to deliver irradiated tumor cells as an antigen source while simultaneously releasing GM-CSF and CpG to recruit DCs and create an immunogenic microenvironment [23] . Significant therapeutic anti-tumor activity against B16-F10 tumors was observed by sustained co-localization of cellular antigen and immunomodulators using this strategy (40% survival with two doses of cryogel vaccine versus 0% in unimmunized mice).
Biomaterial delivery strategies can overcome challenges associated with mucosal vaccination to more effectively treat mucosal tumors. Cancers frequently arise in mucosal tissues, and optimal vaccine-induced T cell homing to these tumors requires mucosal vaccination [24] . Particlebased vaccination at the mucosa can bypass hurdles associated with soluble vaccination such as dilution by mucosal secretions and degradation by mucosal enzymes, leading to improved antigen and adjuvant uptake by DCs at mucosal sites before clearance. For example, pulmonary vaccination with nanoparticle (NP)-bound antigens led to increased capture by pulmonary DCs and generated higher numbers of antigen-specific T cells that homed to the lungs relative to soluble vaccines [25] . Similarly, a multilayered liposomal vaccine encapsulating antigen and hydrophobic monophosphoryl lipid A (MPLA) as an adjuvant [26] was delivered intratracheally with soluble polyinosinic-polycytidylic acid (poly(I:C)) as an additional adjuvant [27] . Liposomal antigen delivery showed vastly improved uptake by lungresident APCs, generated T cells with increased expression of mucosal homing receptors, and improved T cell trafficking to the lungs, relative to treatment with soluble vaccine.
Biomaterials strategies can be used when delivering cells for ACT into peripheral tissues to improve their survival and proliferation. Ex vivo expanded anti-tumor T cells show poor persistence and function when reintroduced into the circulation. Systemic treatment with cytokines such as interleukin 2 (IL-2) can support the T cells, but also produces patient morbidity. However, ex vivo coupling of growth factor-releasing NPs to T cells has been shown to support their subsequent expansion and function after transfer in vivo [28] . Alternatively, efficient direct in vivo targeting of adoptively transferred T cells Porous scaffolds for dendritic cell programming in the periphery. A subcutaneously delivered porous biomaterial scaffold that releases a chemoattractant recruits naïve dendritic cells (DCs) into its void space. Scaffold-resident DCs are exposed to tumor antigens and adjuvants, resulting in increased presentation of peptides on major histocompatibility complex (MHC-peptide) and phenotypic maturation. Mature DCs traffic out of the scaffold to lymph nodes where they can stimulate anti-tumor immunity.
was achieved by PEGylated liposomes decorated with IL-2-Fc, as both a targeting and stimulatory ligand [29] . IL-2-Fc liposomes showed superior expansion of adoptively transferred T cells relative to free IL-2 and allowed multiple waves of in vivo T cell expansion with repeated dosing. Recently, a biomaterials scaffold was used to deploy CAR T cells in tumor resection beds and near sites of multifocal disease [30 ] . This porous alginate scaffold was functionalized with integrin ligands for ex vivo T cell adhesion and loading, and contained embedded microparticles that presented immobilized stimulatory antibodies (anti-CD3, CD28, CD137) and released a soluble cue that supported T cell expansion in vivo (IL-15 superagonist). Scaffold-mediated cell delivery increased T cell expansion 100-fold relative to freely injected T cells, leading to improved disease control in breast and ovarian cancer models relative to bolus delivered ACT.
Targeting LN antigen presenting cells
LNs are the primary site of initiation of adaptive immunity, and appropriate antigen presentation at this site after vaccination is crucial to CTL generation [31] . In addition to direct antigen acquisition and trafficking to the LN by migratory peripheral DCs, LN-resident APCs screen lymph fluid for antigens and danger signals. Soluble vaccine components administered in the skin may bypass capture in the LN by APCs, and particulate formulations can be used to improve their retention. For example, intralymph node injection of adjuvant-releasing microparticles improves adjuvant accumulation in LNs, DC activation, and T cell priming compared to soluble intramuscular or intralymph node injection [32] . Alternatively, engineered NPs of the appropriate physical and surface properties, size range (10-100 nm), and targeting ligands can efficiently drain to LN and be captured by APCs after injection in the skin [33] [34] [35] [36] [37] [38] (Figure 3 ). LN-draining NPs can deliver antigens and adjuvants to LN-resident APCs to prime anti-tumor T cell responses [39] . A recent study used LN-draining PEGylated liposomes to co-encapsulate model antigen and a cyclic dinucleotide (CDN) adjuvant [40] . LN-resident DCs and macrophages captured subcutaneously injected NPs, increasing LN accumulation of CDN 15-fold relative to soluble CDN injection. Co-delivery of CDN-containing NPs with ovalbumin led to a substantial antigen-specific T cell responses (ovalbumin-specific CD8+ T cells in peripheral blood: 15% with NP-CDN and ovalbumin versus 5% with soluble CDN and ovalbumin) and an improved median survival in an ovalbumin-expressing tumor EG.7 lymphoma model (29 days with NP-CDN and ovalbumin versus 17 days with soluble CDN and ovalbumin).
The tumor-draining LN (TDLN), although bathed constantly in tumor antigen, can be a location of immune tolerance generation [41] and efforts have been made to deliver pro-inflammatory stimuli to APCs in the TDLN to instead generate anti-tumor immune response activation. Pluronic-stabilized poly(propylene sulfide)-core NPs loaded with adjuvants were injected intradermally and drained to the TDLN of subcutaneous B16-F10 tumors [42 ] . CpG-loaded NPs increased the number of activated DCs in the TDLN and the quantity of favorable Th1 polarized CD4+ T cells and antigen-specific CD8+ T cells in the tumor, slowing tumor growth. Additional studies with this NP system have shown that the TDLN is a superior site for vaccination with exogenous tumor antigens, relative to non-TDLNs, further motivating investigation of TDLNs as a site for therapeutic intervention [43] .
Recently, a molecular vaccine approach exploited the ability of serum albumin to effectively traffic bound proteins to LNs [44 ] . By creating conjugates of antigen or adjuvant with lipid domains that bind serum albumin, subcutaneously injected vaccine components were efficiently delivered to LNs and accumulated within resident APCs. This approach produced antigen-specific CD8+ T cell responses of unprecedented magnitude for a molecular vaccine (e.g. HPV E7 protein-specific T cells in peripheral blood: 30% with E7 long peptide lipid conjugate and CpG lipid conjugate versus 5% with E7 long peptide and CpG), and showed significantly delayed tumor growth in a number of tumor models tested.
Immunomodulation in the tumor microenvironment (TME)
The immunosuppressive TME limits the function of tumor-infiltrating APCs and T cells [45] , but biomaterials may allow one to modify this microenvironment. Mechanisms of normal tumor immune evasion include changes in antigen repertoire, downregulation of surface MHC Ipeptide complexes, restriction of T cell infiltration, expression of T cell inhibitory ligands, recruitment of immunosuppressive cells, maintenance of metabolically unfavorable conditions, and the elaboration of immunosuppressive cytokines and enzymes that promote APC and T cell dysfunction. Therapeutic delivery of immunomodulators to the TME can potentially be used to overcome these mechanisms.
Biomaterials strategies can improve the activity of proinflammatory drugs that act on APCs in the TME, relative to systemic or locally injected soluble formulations (Figure 4a ). Improved local retention of such agents increases their effect on tumor-infiltrating APCs and reduces toxicity resulting from leakage into systemic circulation from the injection site. For example, while intratumorally injected CpG rapidly leaked from the TME, CpG that was modified with a diacyl lipid inserted into cell membranes and remained localized in the TME, resulting in improved anti-tumor activity [46] . In another approach, liposomes were designed to present an APCstimulating CD40 antibody in combination with CpG when injected at tumors [47] . This produced an increase in median survival in a B16-F10 model (45 days with anti-CD40/CpG liposomes versus 35 days with soluble anti-CD40/CpG versus 19 days with PBS treatment), while diminishing systemic dissemination of these immunostimulants and reducing toxicity compared to soluble formulations. Recently, cationized protein or peptide antigens was electrostatically associated with a DNA hydrogel containing CpG sequences and delivered to the TME [48] . The intrinsic adjuvant activity of the CpG sequences in the hydrogel and controlled release of cationic peptide antigen at the site of ovalbuminexpressing EG.7 lymphoma tumors resulted in an increased fraction of surviving mice (65% with cationized peptide/CpG-gel versus 15% with native peptide/CpGgel versus 0% with cationized peptide/GpC-gel).
T cell function within the TME can be improved by locally delivering stimulatory cues and blocking immunosuppressive pathways using biomaterials (Figure 4b ). Liposome tethering of IL-2-Fc and an agonistic antibody against CD137 allowed their retention at the tumor and TDLN after intratumoral injection, preventing fatal systemic toxicity associated with bolus injection of these agents [49 ] . Remarkably, this approach caused CD8+ T cells to infiltrate both treated and contralateral untreated B16-F10 melanoma tumors, inhibiting tumor growth. The ability of biomaterials to be multifunctional has been demonstrated with core-shell particles that released water-soluble IL-2 and a hydrophobic small molecule inhibitor of the immunosuppressive TGF-b pathway [50] . When injected intravenously, these NPs accumulated in lung tumors, presumably due to leaky tumor vasculature, and increased the number of activated CD8+ T cells and natural killer (NK) cell-mediated tumor destruction. Ex vivo conjugation of T cells with drug-releasing NPs that provide locally high concentrations of immunomodulators at the cell surface can also protect their function in the TME [51] . T cells coupled with NPs releasing an inhibitor of a T cell suppressive pathway (Shp1/Shp2) showed increased proliferation in the TME and reduced tumor growth. Recently, an alginate hydrogel was used to locally deliver anti-PD-1 directly to its presumed site of action in the TME [52] . Combination delivery of anti-PD-1 and the anti-inflammatory drug celecoxib at the tumor using a gel resulted in increased effector T cell infiltration, a reduction in inhibitory immune cells, and improved overall survival in mice bearing B16-F10 tumors (55% with drug-releasing gel versus 10% with soluble drugs) or 4T1 breast cancer tumor (30% with drug-releasing gel versus 0% with soluble drugs).
Conclusions and outlook
Biomaterials-based strategies show tremendous promise for improving the spatiotemporal delivery of immunomodulators to enhance their safety and efficacy in cancer immunotherapy. Additionally, the multifunctionality provided by biomaterials can be used to impact immune signaling programs at many stages. A number of biomaterials strategies tested in murine models are grounded in principles that apply to the human immune system, warranting non-human primate and clinical testing. Biomaterials approaches will also probably be tested for their ability to enhance the efficacy of clinically validated checkpoint inhibitor therapies. Strategies that use raw materials previously approved by the FDA for medical applications will probably be translated more readily, and will be the focus of initial research. Further, advances in cancer immunology will continue to inform novel immunoengineering strategies. For example, recently developed methods to determine patient-specific mutated antigens can feed back directly into the design of personalized biomaterials-based vaccines with increased safety and efficacy [53] . Improved collaboration between bioengineers, industry, immunologists and clinicians will accelerate the pace of engineered immunotherapy development and translation.
